Følg
Mikkel Bring Christensen
Mikkel Bring Christensen
MD, PhD, Medical Specialist
Verificeret mail på dadlnet.dk
Titel
Citeret af
Citeret af
År
Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
T Vilsbøll, M Christensen, AE Junker, FK Knop, LL Gluud
Bmj 344, 2012
10492012
Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
T Vilsbøll, M Christensen, AE Junker, FK Knop, LL Gluud
Bmj 344, 2012
10492012
Medication review in hospitalised patients to reduce morbidity and mortality
M Christensen, A Lundh
The Cochrane Library, 2016
4582016
Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans
M Christensen, L Vedtofte, JJ Holst, T Vilsbøll, FK Knop
Diabetes 60 (12), 3103-3109, 2011
3462011
Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies
S Calanna, M Christensen, JJ Holst, B Laferrere, LL Gluud, T Vilsbøll, ...
Diabetologia 56, 965-972, 2013
2992013
Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis
H Storgaard, LL Gluud, C Bennett, MF Grøndahl, MB Christensen, ...
PLoS One 11 (11), e0166125, 2016
2632016
Regulation of glucagon secretion by incretins
JJ Holst, M Christensen, A Lund, J De Heer, B Svendsen, U Kielgast, ...
Diabetes, Obesity and Metabolism 13, 89-94, 2011
1902011
Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes
S Calanna, M Christensen, JJ Holst, B Laferrère, LL Gluud, T Vilsbøll, ...
Diabetes Care 36 (10), 3346-3352, 2013
1692013
Evidence of extrapancreatic glucagon secretion in man
A Lund, JI Bagger, NJ Wewer Albrechtsen, M Christensen, M Grøndahl, ...
Diabetes 65 (3), 585-597, 2016
1672016
Glucagon and type 2 diabetes: the return of the alpha cell
A Lund, JI Bagger, M Christensen, FK Knop, T Vilsbøll
Current diabetes reports 14, 1-7, 2014
1422014
Separate and combined glucometabolic effects of endogenous glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 in healthy individuals
LS Gasbjerg, MM Helsted, B Hartmann, MH Jensen, MBN Gabe, ...
Diabetes 68 (5), 906-917, 2019
1382019
Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans
MJ Bak, NW Albrechtsen, J Pedersen, B Hartmann, M Christensen, ...
European Journal of Endocrinology 170 (4), 529-538, 2014
1362014
Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus.
M Christensen, FK Knop, JJ Holst, T Vilsboll
IDrugs: the investigational drugs journal 12 (8), 503-513, 2009
1262009
Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes
E Jimenez-Solem, MH Rasmussen, M Christensen, FK Knop
Curr Opin Mol Ther 12 (6), 790-7, 2010
1252010
Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans
A Nissen, M Christensen, FK Knop, T Vilsbøll, JJ Holst, B Hartmann
The Journal of Clinical Endocrinology & Metabolism 99 (11), E2325-E2329, 2014
1102014
Lixisenatide for type 2 diabetes mellitus
M Christensen, FK Knop, T Vilsbøll, JJ Holst
Expert opinion on investigational drugs 20 (4), 549-557, 2011
1092011
Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes
MB Christensen, S Calanna, JJ Holst, T Vilsbøll, FK Knop
The Journal of Clinical Endocrinology & Metabolism 99 (3), E418-E426, 2014
1022014
Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes
MB Christensen, S Calanna, JJ Holst, T Vilsbøll, FK Knop
The Journal of Clinical Endocrinology & Metabolism 99 (3), E418-E426, 2014
1022014
Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study
NC Bergmann, A Lund, LS Gasbjerg, ECE Meessen, MM Andersen, ...
Diabetologia 62, 665-675, 2019
922019
Species‐specific action of (Pro3) GIP–a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors
AH Sparre‐Ulrich, LS Hansen, B Svendsen, M Christensen, FK Knop, ...
British journal of pharmacology 173 (1), 27-38, 2016
902016
Systemet kan ikke foretage handlingen nu. Prøv igen senere.
Artikler 1–20